Short answer: A compounded cream combining allantoin 0.1%, benzocaine 0.5% and menthol 0.3% is a low-strength topical preparation designed for mild, localised skin discomfort where a gentle anaesthetic and soothing effect is desired without the high anaesthetic load of stronger formulations. Allantoin is included for its skin-conditioning properties, benzocaine at 0.5% provides a mild surface anaesthetic effect, and menthol 0.3% delivers a cooling counterirritant sensation. The preparation is made as a non-sterile cream for a named patient on a doctor’s prescription under Good Compounding Practice (GCP).
Why compound a low-strength allantoin-anaesthetic cream
Commercial topical products for mild skin discomfort typically carry a single active at a fixed concentration. When a prescriber wants to combine a skin-soothing agent with a low-dose anaesthetic and a cooling counterirritant — at concentrations gentler than standard anaesthetic creams — compounding is the formulation route. The rationale is a preparation suitable for sensitive or compromised skin where stronger anaesthetic concentrations would be inappropriate, and where a multi-ingredient approach at low strength is preferred over a single-agent product.
Clinical indications and target patients
This formulation is typically prescribed for mild, localised skin discomfort — irritated or sensitive skin where a gentle anaesthetic and soothing effect is desired. Target patients include those with skin that does not tolerate higher-strength anaesthetic preparations, or where the prescriber’s intent is a mild, soothing preparation rather than a procedural anaesthetic. The low benzocaine concentration (0.5%) places this formulation far below the methaemoglobinaemia risk threshold associated with higher benzocaine concentrations.
Allantoin has been studied for its wound-healing properties. Research demonstrated a profile of wound healing promotion in animal models, supporting its inclusion as a skin-conditioning component (Araújo et al., Acta Cirúrgica Brasileira, 2010; PMID 20877959). A recent formulation study explored a lidocaine-allantoin hydrogel for wound healing applications, reflecting the rationale for combining allantoin with anaesthetic actives in a single preparation (Arpa et al., Pharmaceutics, 2025; PMID 41471121).
Dosing and application guidance
The cream is applied as a thin layer to the affected area, typically 2–3 times daily. A practical amount is approximately 1–2 g per application to a localised area. The low concentrations of all three actives mean the cumulative systemic exposure is minimal, but the prescriber should still specify the maximum daily amount and the total application area. Patients should be counselled to apply to intact skin and wash hands after use.
Formulation notes
Vehicle and base selection
An emollient cream base is typically selected for this formulation, as the low concentrations of all three actives do not require a penetration-enhancing vehicle. Allantoin is poorly soluble in water — a suspension or emulsion base is appropriate. Menthol is lipophilic and dissolves readily in the cream base. The base should be selected for skin tolerability, as the target patient population may have sensitive skin.
Preservative considerations
A preservative system appropriate to the water content of the cream base should be included. For patients with known preservative sensitivities, the prescriber can specify preservative exclusions in the formulation brief, and the pharmacy can advise on alternative preservative systems or anhydrous base options.
Stability and beyond-use dating
The BUD is typically assigned at 30–90 days for a non-sterile cream with preservative, depending on water activity and stability data. Allantoin is generally stable in cream bases. Benzocaine at 0.5% is an ester anaesthetic subject to hydrolysis in aqueous environments, though the low concentration reduces the practical impact. The preparation should be stored at room temperature and protected from light.
Compatibility and interactions
Allantoin, benzocaine and menthol are pharmaceutically compatible in a cream base. At 0.5% benzocaine, the methaemoglobinaemia risk is substantially lower than at the 20% concentration used in stronger anaesthetic formulations, but the same ester-anaesthetic counselling applies with reduced intensity. Menthol can cause local irritation in some individuals, though at 0.3% this is uncommon.
Safety and counselling
Methaemoglobinaemia — low risk but not zero
At 0.5% benzocaine, the methaemoglobinaemia risk is substantially lower than at higher benzocaine concentrations. A retrospective review of 28,478 transoesophageal echocardiograms documented benzocaine-induced methaemoglobinaemia, though the cases involved much higher benzocaine concentrations applied to mucosal surfaces (Kane et al., Archives of Internal Medicine, 2007; PMID 17923598). At 0.5% on intact skin, the risk is minimal, but prescribers should still counsel patients on signs of methaemoglobinaemia (cyanosis, dyspnoea, fatigue) and avoid use in patients with known G6PD deficiency or methaemoglobin reductase deficiency.
Local irritation
Menthol at 0.3% can cause a cooling sensation that most patients find pleasant, but a small number may experience local irritation. Allantoin is generally well tolerated and is included in the formulation for its skin-conditioning properties. If irritation occurs, patients should discontinue use and consult their prescriber.
Systemic absorption
At the concentrations in this formulation, systemic absorption of benzocaine and menthol is minimal when applied to intact skin in the recommended amounts. The prescriber should still specify the maximum daily amount and total application area, particularly for patients with compromised skin barriers.
Documentation checklist for prescribers
- Named patient and prescriber details
- Active ingredients and exact strengths: allantoin 0.1%, benzocaine 0.5%, menthol 0.3%
- Dosage form: cream (specify base preference and any preservative exclusions)
- Clinical rationale: why a low-strength combination is preferred over a commercial single-agent product
- Application site and area: anatomical location and maximum surface area
- Amount per application and frequency
- Known sensitivities: ester anaesthetic allergies, menthol sensitivity, preservative exclusions
- Safety notes: methaemoglobinaemia counselling (low risk), local irritation monitoring
- Review plan: follow-up timing and reassessment triggers
Discussing an allantoin-anaesthetic cream preparation with Lynnity
Lynnity prepares non-sterile compounded topical creams — including low-strength soothing and anaesthetic combinations — for named patients on a registered doctor’s prescription, under Good Compounding Practice (GCP). The pharmacy can advise on emollient base selection for sensitive skin, preservative system options, and stability and beyond-use dating for the specific combination. Where a prescriber is considering a related preparation — for example, a compounded eczema cream with specific excipient exclusions, or a liposomal delivery form of a topical active — the pharmacy can prepare these on prescription as well. The conversation begins with the prescription and formulation brief sent to the pharmacy; the pharmacists can then advise on practicality and any compatibility or stability concerns before proceeding.
Frequently asked questions
Is 0.5% benzocaine safe compared to higher-strength anaesthetic creams?
At 0.5%, the benzocaine concentration is forty times lower than the 20% used in stronger compounded anaesthetic formulations. The methaemoglobinaemia risk associated with benzocaine is dose- and site-dependent; a review of 28,478 procedures documented cases at much higher concentrations on mucosal surfaces (Kane et al., 2007; PMID 17923598). At 0.5% on intact skin, the risk is minimal, though standard counselling on signs of methaemoglobinaemia still applies, and the preparation should be avoided in patients with G6PD deficiency.
What is allantoin’s role in this formulation?
Allantoin is included as a skin-conditioning agent. Research in animal models demonstrated a profile of wound healing promotion (Araújo et al., 2010; PMID 20877959), and a recent formulation study explored combining allantoin with anaesthetic actives in a hydrogel (Arpa et al., 2025; PMID 41471121). At 0.1%, allantoin is included for its soothing and skin-conditioning properties rather than as a primary analgesic.
Can this cream be used on broken or irritated skin?
The cream is intended for application to intact skin. On compromised skin, systemic absorption of benzocaine and menthol increases, though the low concentrations reduce the practical significance. The prescriber should assess skin integrity before prescribing and document the application site. If the skin is broken, the prescriber should consider whether a topical anaesthetic preparation is appropriate at all.
How often can this cream be applied?
Typical application is 2–3 times daily to the affected area, in a thin layer of approximately 1–2 g per application. The prescriber should specify the exact frequency and maximum daily amount in the prescription. At the low concentrations in this formulation, the cumulative systemic exposure is minimal when applied to intact skin within these guidelines.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
To discuss a patient-specific allantoin-anaesthetic cream preparation — or to flag a formulation concern before prescribing — consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.